Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections

DV. Vasina, NP. Antonova, VA. Gushchin, AV. Aleshkin, MV. Fursov, AD. Fursova, PG. Gancheva, IV. Grigoriev, P. Grinkevich, AV. Kondratev, AV. Kostarnoy, AM. Lendel, VV. Makarov, MA. Nikiforova, AA. Pochtovyi, T. Prudnikova, TA. Remizov, NV....

. 2024 ; 31 (1) : 75. [pub] 20240724

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019688

Grantová podpora
Contract no. 0373100122120000008 of 08 April 2020 Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency
no. 0373100122119000013 of 15 May 2019 Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency

BACKGROUND: Among the non-traditional antibacterial agents in development, only a few targets critical Gram-negative bacteria such as carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii or cephalosporin-resistant Enterobacteriaceae. Endolysins and their genetically modified versions meet the World Health Organization criteria for innovation, have a novel mode of antibacterial action, no known bacterial cross-resistance, and are being intensively studied for application against Gram-negative pathogens. METHODS: The study presents a multidisciplinary approach, including genetic engineering of LysECD7-SMAP and production of recombinant endolysin, its analysis by crystal structure solution following molecular dynamics simulations and evaluation of antibacterial properties. Two types of antimicrobial dosage forms were formulated, resulting in lyophilized powder for injection and hydroxyethylcellulose gel for topical administration. Their efficacy was estimated in the treatment of sepsis, and pneumonia models in BALB/c mice, diabetes-associated wound infection in the leptin receptor-deficient db/db mice and infected burn wounds in rats. RESULTS: In this work, we investigate the application strategies of the engineered endolysin LysECD7-SMAP and its dosage forms evaluated in preclinical studies. The catalytic domain of the enzyme shares the conserved structure of endopeptidases containing a putative antimicrobial peptide at the C-terminus of polypeptide chain. The activity of endolysins has been demonstrated against a range of pathogens, such as Klebsiella pneumoniae, A. baumannii, P. aeruginosa, Staphylococcus haemolyticus, Achromobacter spp, Burkholderia cepacia complex and Haemophylus influenzae, including those with multidrug resistance. The efficacy of candidate dosage forms has been confirmed in in vivo studies. Some aspects of the interaction of LysECD7-SMAP with cell wall molecular targets are also discussed. CONCLUSIONS: Our studies demonstrate the potential of LysECD7-SMAP therapeutics for the systemic or topical treatment of infectious diseases caused by susceptible Gram-negative bacterial species and are critical to proceed LysECD7-SMAP-based antimicrobials trials to advanced stages.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019688
003      
CZ-PrNML
005      
20241024110650.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12929-024-01065-y $2 doi
035    __
$a (PubMed)39044206
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vasina, Daria V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia. d.v.vasina@gmail.com $1 https://orcid.org/0000000319650700
245    10
$a Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections / $c DV. Vasina, NP. Antonova, VA. Gushchin, AV. Aleshkin, MV. Fursov, AD. Fursova, PG. Gancheva, IV. Grigoriev, P. Grinkevich, AV. Kondratev, AV. Kostarnoy, AM. Lendel, VV. Makarov, MA. Nikiforova, AA. Pochtovyi, T. Prudnikova, TA. Remizov, NV. Shevlyagina, AE. Siniavin, NS. Smirnova, AA. Terechov, AP. Tkachuk, EV. Usachev, AM. Vorobev, VS. Yakimakha, SM. Yudin, AA. Zackharova, VG. Zhukhovitsky, DY. Logunov, AL. Gintsburg
520    9_
$a BACKGROUND: Among the non-traditional antibacterial agents in development, only a few targets critical Gram-negative bacteria such as carbapenem-resistant Pseudomonas aeruginosa, Acinetobacter baumannii or cephalosporin-resistant Enterobacteriaceae. Endolysins and their genetically modified versions meet the World Health Organization criteria for innovation, have a novel mode of antibacterial action, no known bacterial cross-resistance, and are being intensively studied for application against Gram-negative pathogens. METHODS: The study presents a multidisciplinary approach, including genetic engineering of LysECD7-SMAP and production of recombinant endolysin, its analysis by crystal structure solution following molecular dynamics simulations and evaluation of antibacterial properties. Two types of antimicrobial dosage forms were formulated, resulting in lyophilized powder for injection and hydroxyethylcellulose gel for topical administration. Their efficacy was estimated in the treatment of sepsis, and pneumonia models in BALB/c mice, diabetes-associated wound infection in the leptin receptor-deficient db/db mice and infected burn wounds in rats. RESULTS: In this work, we investigate the application strategies of the engineered endolysin LysECD7-SMAP and its dosage forms evaluated in preclinical studies. The catalytic domain of the enzyme shares the conserved structure of endopeptidases containing a putative antimicrobial peptide at the C-terminus of polypeptide chain. The activity of endolysins has been demonstrated against a range of pathogens, such as Klebsiella pneumoniae, A. baumannii, P. aeruginosa, Staphylococcus haemolyticus, Achromobacter spp, Burkholderia cepacia complex and Haemophylus influenzae, including those with multidrug resistance. The efficacy of candidate dosage forms has been confirmed in in vivo studies. Some aspects of the interaction of LysECD7-SMAP with cell wall molecular targets are also discussed. CONCLUSIONS: Our studies demonstrate the potential of LysECD7-SMAP therapeutics for the systemic or topical treatment of infectious diseases caused by susceptible Gram-negative bacterial species and are critical to proceed LysECD7-SMAP-based antimicrobials trials to advanced stages.
650    _2
$a zvířata $7 D000818
650    12
$a gramnegativní bakteriální infekce $x farmakoterapie $7 D016905
650    _2
$a myši $7 D051379
650    12
$a endopeptidasy $x farmakologie $x aplikace a dávkování $7 D010450
650    12
$a myši inbrední BALB C $7 D008807
650    12
$a gramnegativní bakterie $x účinky léků $7 D006090
650    _2
$a antibakteriální látky $x farmakologie $x aplikace a dávkování $7 D000900
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a proteinové inženýrství $x metody $7 D015202
655    _2
$a časopisecké články $7 D016428
700    1_
$a Antonova, Nataliia P $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Gushchin, Vladimir A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia $u Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
700    1_
$a Aleshkin, Andrey V $u G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Moscow, Russia
700    1_
$a Fursov, Mikhail V $u State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia
700    1_
$a Fursova, Anastasiia D $u State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia
700    1_
$a Gancheva, Petya G $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Grigoriev, Igor V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Grinkevich, Pavel $u Faculty of Science, University of South Bohemia in Ceske Budejovice, Ceske Budejovice, Czech Republic
700    1_
$a Kondratev, Alexey V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Kostarnoy, Alexey V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Lendel, Anastasiya M $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia $u Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
700    1_
$a Makarov, Valentine V $u Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia
700    1_
$a Nikiforova, Maria A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Pochtovyi, Andrei A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia $u Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia
700    1_
$a Prudnikova, Tatiana $u Faculty of Science, University of South Bohemia in Ceske Budejovice, Ceske Budejovice, Czech Republic
700    1_
$a Remizov, Timofey A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Shevlyagina, Natalia V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Siniavin, Andrei E $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Smirnova, Nina S $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Terechov, Alexander A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Tkachuk, Artem P $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Usachev, Evgeny V $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Vorobev, Aleksei M $u G.N. Gabrichevsky Moscow Research Institute for Epidemiology and Microbiology, Moscow, Russia
700    1_
$a Yakimakha, Victoria S $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Yudin, Sergey M $u Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia
700    1_
$a Zackharova, Anastasia A $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Zhukhovitsky, Vladimir G $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia $u Russian Medical Academy of Continuing Professional Education (RMANPO), Ministry of Public Health, Moscow, Russia
700    1_
$a Logunov, Denis Y $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia
700    1_
$a Gintsburg, Alexander L $u N.F. Gamaleya National Research Centre for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russia $u Department of Infectiology and Virology, Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
773    0_
$w MED00011535 $t Journal of biomedical science $x 1423-0127 $g Roč. 31, č. 1 (2024), s. 75
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39044206 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110644 $b ABA008
999    __
$a ok $b bmc $g 2202115 $s 1231661
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 31 $c 1 $d 75 $e 20240724 $i 1423-0127 $m Journal of biomedical science $n J Biomed Sci $x MED00011535
GRA    __
$a Contract no. 0373100122120000008 of 08 April 2020 $p Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency
GRA    __
$a no. 0373100122119000013 of 15 May 2019 $p Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...